IL-1 Rrp2 Overview
Molecule Name
Interleukin-36 receptor
Synonyms
IL-1 R6,IL-1 Rrp2,IL1RL2,IL-1RL2,IL1Rrp2,IL-1Rrp2,IL1RRP2,IL-36R
Drug Development Progress
Drugs in Clinical Trials4
Approved Drugs1
Highest Development StageApproved
Target Synonym
Interleukin-1 Receptor-Related Protein 2，Interleukin-1 Receptor-Like 2，IL-1Rrp2，Interleukin 1 Receptor Like 2，EC:3.2.2.6，IL-36R，IL1RRP2，IL-36 Receptor，IL1R-Rp2，IL1RL2，IL-1 Receptor-Related Protein 2
Background
The Interleukin 1 receptor family (IL-1 R) comprises at least eleven members including IL-1 RI (IL-1 R1), IL-1 RII (IL-1 R2), IL-1 RAcP (IL‑1 R3), ST2 (T1/IL-1 R4), IL-18 Ra (IL-1 Rrp/IL-1 R5), IL-1 Rrp2 (IL-1 RL2/IL-1 R6), IL-18 Rb (AcPL/IL-1 R7), IL-1RAPL‑1 (TIGIRR‑2/IL‑1 R8), and TIGIRR-1 (IL-1 R9). All family members possess three immunoglobulin (Ig)-like domains in their extracellular region. Most members also have an intracellular TIR (Toll-like receptor/IL-1 receptor signaling) domain that is also conserved in the Toll-like receptor family. Related proteins, SIGIRR (single Ig domain-containing IL-1 R-related molecule) and IL-18BP, differ from the other members by having only one Ig domain.
IL-1 Rrp2 Product List
You Have Viewed 0 Of 0 Results
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| HB-0043 | HB-0043 | Phase 2 Clinical | HuaBo Biopharm Co Ltd | Acne Vulgaris; Arthritis, Rheumatoid; Autoimmune Diseases; Dermatitis, Atopic; Hidradenitis Suppurativa; Lupus Erythematosus, Systemic; Lupus Nephritis; Psoriasis; Renal Insufficiency, Chronic | Details |
| SHR-1139 | SHR1139; SHR-1139 | Phase 2 Clinical | Guangdong Hengrui Pharmaceutical Co Ltd | Colitis, Ulcerative; Plaque psoriasis; Psoriasis; Pyoderma Gangrenosum | Details |
| TQH-2929 | TQH-2929; TQH2929 | Phase 2 Clinical | Nanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group | Generalised pustular psoriasis; Psoriasis; Pustular psoriasis | Details |
| IMG-008 | IMG008 | Phase 1 Clinical | Ikena Oncology Inc | Autoimmune Diseases; Inflammation | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Spesolimab | BI-655130 | Approved | C.H. Boehringer Sohn Ag & Co. Kg | 圣利卓, Spevigo | United States | Psoriasis | Boehringer Ingelheim Pharmaceuticals Inc | 2022-09-01 | Colitis, Ulcerative; Crohn Disease; Dermatitis, Atopic; Generalised pustular psoriasis; Hidradenitis Suppurativa; Netherton Syndrome; Palmoplantar pustulosis; Psoriasis; Pyoderma Gangrenosum | Details |